GlassScriptPhysician profile
Roben Leaverton
NPI 1891422440
$2,233.31
in general payments reported to CMS, 2019-2025
29 companies · $210 in 2025
The $210 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $512 · 2023: $1,270 · 2024: $242 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,232 · Education: $490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,231.65 |
| Education | $489.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $465.73 | 2022-2025 | Jakafi, Pemazyre, Monjuvi |
| Seagen INC. | $172.68 | 2022-2023 | Tukysa, Padcev |
| Beigene USA, INC. | $132.57 | 2022-2023 | Brukinsa |
| Amgen INC. | $122.89 | 2023 | Lumakras, Vectibix, Xgeva |
| Sirtex Medical INC | $120.91 | 2025 | Sir-Spheres Microspheres |
| Genentech USA, INC. | $108.32 | 2023-2025 | Polivy, Itovebi, Lunsumio |
| Takeda Pharmaceuticals U.S.A., INC. | $102.91 | 2023 | Ninlaro |
| Astrazeneca Pharmaceuticals LP | $101.59 | 2022-2023 | Imfinzi |
| Novartis Pharmaceuticals Corporation | $96.94 | 2023 | |
| Lilly USA, LLC | $91.25 | 2023-2024 | Jaypirca, Verzenio, Retevmo |
| Astellas Pharma US INC | $90.43 | 2023 | Xospata |
| Jazz Pharmaceuticals INC. | $63.78 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.98 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $54.30 | 2023-2025 | Keytruda, Lynparza |
| Pfizer INC. | $51.07 | 2022-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $49.06 | 2023 | Jemperli, Zejula |
| Eisai INC. | $42.81 | 2022-2023 | |
| Abbvie INC. | $42.05 | 2023-2024 | |
| Blueprint Medicines Corporation | $38.85 | 2023 | Ayvakit |
| Genzyme Corporation | $37.01 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.72 | 2022-2023 | Gilotrif |
| Pharmacyclics LLC, An Abbvie Company | $28.33 | 2023 | Imbruvica |
| Morphosys, US INC. | $20.93 | 2023 | Monjuvi |
| Pharmaessentia USA Corporation | $20.81 | 2023 | Besremi |
| Sobi, INC | $20.39 | 2023 | |
| Daiichi Sankyo INC. | $16.70 | 2024 | Injectafer |
| Celgene Corporation | $15.70 | 2023 | Pomalyst |
| Deciphera Pharmaceuticals INC. | $15.17 | 2023 | Qinlock |
| E.R. Squibb & Sons, L.L.C. | $14.43 | 2023 | Opdivo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roben Leaverton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.